| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
36,651,000 |
| Market
Cap: |
570.29(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$11.84 - $28.66 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Quanterix is a life sciences company that has developed digital immunoassay platforms. Co.'s platforms are based on its proprietary digital Simoa detection technology. Co. provides the following three Simoa instruments: HD-X, which is based on Co.'s bead-based technology, and assays run on the HD-X are fully automated; SR-X, which utilizes the same Simoa bead-based technology and assay kits as the HD-X in a compact benchtop form with a range of applications; and SP-X, which is based on Co.'s planar array technology, which allows for multiplexing capabilities for oncology and immunology applications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
20,200 |
639,331 |
| Total Buy Value |
$0 |
$0 |
$501,978 |
$6,053,841 |
| Total People Bought |
0 |
0 |
1 |
7 |
| Total Buy Transactions |
0 |
0 |
1 |
8 |
| Total Shares Sold |
2,500 |
5,000 |
5,000 |
10,265 |
| Total Sell Value |
$60,025 |
$119,770 |
$119,770 |
$214,084 |
| Total People Sold |
1 |
1 |
1 |
5 |
| Total Sell Transactions |
2 |
4 |
4 |
15 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Fry John J |
General Counsel & Secretary |
• – – |
2022-04-01 |
4 |
S |
$29.79 |
$15,611 |
D/D |
(524) |
30,229 |
|
67% |
|
| Crandell Keith |
|
– • • |
2022-04-01 |
4 |
A |
$30.47 |
$14,991 |
D/D |
492 |
118,749 |
|
- |
|
| Mcconnell Sarah H |
|
– • – |
2022-04-01 |
4 |
A |
$30.47 |
$13,742 |
D/D |
451 |
15,291 |
|
- |
|
| Meister Paul M |
|
– • – |
2022-04-01 |
4 |
A |
$30.47 |
$14,991 |
D/D |
492 |
17,414 |
|
- |
|
| Mattoon Dawn |
Sr. VP, Diagnostics |
• – – |
2022-04-01 |
4 |
S |
$29.79 |
$7,776 |
D/D |
(261) |
36,876 |
|
67% |
|
| Roskey Mark T. |
SVP, Strategic Partnerships |
• – – |
2022-04-01 |
4 |
S |
$29.79 |
$5,095 |
D/D |
(171) |
22,325 |
|
67% |
|
| Hrusovsky E Kevin |
Chairman and CEO |
• • – |
2022-04-01 |
4 |
S |
$29.79 |
$25,860 |
D/D |
(868) |
886,976 |
|
67% |
|
| Duffy David C. |
SVP R&D and CTO |
• – – |
2022-03-23 |
4 |
AS |
$30.00 |
$97,980 |
D/D |
(3,266) |
54,730 |
|
-44% |
|
| Mattoon Dawn |
Sr. VP, Diagnostics |
• – – |
2022-03-01 |
4 |
S |
$31.21 |
$8,399 |
D/D |
(267) |
37,137 |
|
43% |
|
| Fry John J |
General Counsel & Secretary |
• – – |
2022-03-01 |
4 |
S |
$31.21 |
$11,671 |
D/D |
(371) |
30,753 |
|
43% |
|
| Roskey Mark T. |
SVP, Strategic Partnerships |
• – – |
2022-03-01 |
4 |
S |
$31.21 |
$5,222 |
D/D |
(166) |
22,496 |
|
43% |
|
| Hrusovsky E Kevin |
Chairman and CEO |
• • – |
2022-03-01 |
4 |
S |
$31.21 |
$18,530 |
D/D |
(589) |
887,844 |
|
43% |
|
| Roskey Mark T. |
SVP, Strategic Partnerships |
• – – |
2022-02-09 |
4 |
S |
$34.97 |
$10,211 |
D/D |
(292) |
22,662 |
|
52% |
|
| Hrusovsky E Kevin |
Chairman and CEO |
• • – |
2022-02-09 |
4 |
S |
$34.97 |
$47,697 |
D/D |
(1,364) |
888,433 |
|
52% |
|
| Mattoon Dawn |
Sr. VP, Diagnostics |
• – – |
2022-02-09 |
4 |
S |
$34.97 |
$11,120 |
D/D |
(318) |
37,404 |
|
52% |
|
| Fry John J |
General Counsel & Secretary |
• – – |
2022-02-09 |
4 |
S |
$34.97 |
$16,820 |
D/D |
(481) |
31,124 |
|
52% |
|
| Duffy David C. |
SVP R&D and CTO |
• – – |
2022-02-04 |
4 |
AS |
$30.91 |
$100,952 |
D/D |
(3,266) |
57,996 |
|
-48% |
|
| Mattoon Dawn |
Sr. VP, Diagnostics |
• – – |
2022-02-02 |
4 |
S |
$31.21 |
$8,399 |
D/D |
(267) |
37,722 |
|
53% |
|
| Hrusovsky E Kevin |
Chairman and CEO |
• • – |
2022-02-02 |
4 |
S |
$31.21 |
$18,530 |
D/D |
(589) |
889,797 |
|
53% |
|
| Fry John J |
General Counsel & Secretary |
• – – |
2022-02-02 |
4 |
S |
$31.21 |
$11,671 |
D/D |
(371) |
31,605 |
|
53% |
|
| Roskey Mark T. |
SVP, Strategic Partnerships |
• – – |
2022-02-02 |
4 |
S |
$31.21 |
$5,222 |
D/D |
(166) |
22,954 |
|
53% |
|
| Duffy David C. |
SVP R&D and CTO |
• – – |
2022-01-31 |
4 |
AS |
$30.00 |
$97,980 |
D/D |
(3,266) |
61,262 |
|
-43% |
|
| Madaus Martin D |
|
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$18,109 |
D/D |
3,095 |
18,443 |
|
- |
|
| Meister Paul M |
|
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$13,741 |
D/D |
2,992 |
16,922 |
|
- |
|
| Mattoon Dawn |
Sr. VP, Diagnostics |
• – – |
2022-01-03 |
4 |
S |
$41.91 |
$14,877 |
D/D |
(355) |
37,989 |
|
63% |
|
278 Records found
|
|
Page 2 of 12 |
|
|
0.03 (0.19%) 
